<DOC>
	<DOCNO>NCT01718015</DOCNO>
	<brief_summary>Background : The pathogenetic factor underlie development diabetic polyneuropathy ( DP ) remain unclear . Reduced neurotrophic stimulation propose possible mechanism . The neurotrophic factor IGF I II , sCD-163 , NGF , VEGF BDNF essential development regeneration nervous system . In early study reduce concentration IGF-I II blood reduce concentration NGF BDNF muscle skin biopsy find patient DP . Purpose : Our purpose determine concentration biological activity Insulin-like Growth Factor I II ( IGF-I II ) , soluble Cluster Differentiation 163 ( sCD-163 ) , Nerve Growth Factor ( NGF ) , Vascular Endothelial Growth Factor ( VEGF ) Brain-derived Neurotropic Factor ( BDNF ) cerebrospinal fluid blood patient diabetes and/or nerve disease ( especially diabetic polyneuropathy ) well healthy control subject . We furthermore relate finding peripheral nerve function . In addition composition cerebrospinal fluid analyze use mass spectrometry . Hypothesis : We hypothesize DP develops due reduce concentration biological activity neurotrophic factor . We expect concentration IGF-I II , VEGF , NGF BDNF reduce cerebrospinal fluid patient DP compare diabetic patient without damage nervous system healthy control subject . Methods : Study subject consist patient Department Neurology Department Department Clinical Medicine ( Endocrinology Diabetes ) Aarhus University Hospital , Denmark , lumbar puncture perform .</brief_summary>
	<brief_title>Neurotrophic Factors Cerebrospinal Fluid Diabetic Patients With Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<criteria>Patients diabetic polyneuropathy Patients diabetes without peripheral nerve disorder Patients polyneuropathies due diabetes Patients suffer diabetes nerve disease ( control subject ) Patients unspecified nerve disease Other cause development polyneuropathy patient diabetic polyneuropathy Cerebral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Vascular Endothelial Growth Factor</keyword>
	<keyword>Brain-Derived Neurothropic Factor</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>CD-163</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>Peripheral Nervous System Diseases</keyword>
	<keyword>Mass spectrometry</keyword>
</DOC>